Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Rapid Allergy Detector Helps Avoid Penicillin Deaths

By Kenny Walter | October 20, 2016

European researchers have developed a scanning device that will more efficiently detect whether or not a patient is hypersensitive to penicillin. (Credit: COBIOPHAD)

A new scanning device using the latest in photonics technology could help millions of people suffering from penicillin allergies when given the antibiotic incorrectly.

A research team running the Horizon 2020 project COBIOPHAD (Compact Biophotonic Platform for Drug Allergy Diagnosis) has developed a device that will allow healthcare professionals to detect whether a patient is allergic to Beta Lactam Antibiotics (BLCs) quicker and more efficiently.

Photonics21, an association representing European photonics stakeholders, said the new allergy detector is a low-cost, bio-photonic device that will be six times faster and 100 times more efficient than current technology, providing more targeted treatment for the more than 2.5 million people in Europe and 5.4 million in the U.S. suffering from hypersensitivity to BLCs—the most commonly prescribed drugs in the penicillin family.

The device works by reading a compact disc-like cartridge with a laser, similar to the way an everyday CD- ROM drive works in a computer.

The cartridge will recognize a specific Immunoglobulin E (IgE), an antibody produced by the immune system that plays a vital part in the manifestation of allergy, using pre-loaded Beta Ladam reagents.

When the patient’s blood sample is run across the cartridge, the device will send out a signal based on the level of hypersensitivity within the patient for 10 different targeted Beta Lactams.

“The COBIOPHAD device aims to take drug hypersensitivity detection into a new era: compared to current tests our device can deliver a rapid diagnosis of the main allergenic BLCs in less than half an hour, making it six times faster,” Exploitation Manager Ian McKay, Ph.D., said in a statement. “With an improved in vitro diagnostic (IVD), we offer a much more patient-friendly alternative to the invasive and risky in vivo testing.

“The COBIOPHAD approach must reach a sensitivity of 80 percent with a detection limit below 0.1 kU per liter. It deploys an increased multiplexing capability, looking at more samples per disc and examines a greater number of BLCs per sample. As a result, the overall system is 100 times more efficient,” he added.

Many people avoid taking penicillin and its relatives because of allergy fears, where symptoms may include wheezing, coughing, breathing problems, tissue swelling or in more serious cases anaphylaxis, which requires urgent medical attention.

Currently, anaphylaxis leads to 500 to 1,000 deaths per year in the U.S., 20 deaths per year in the U.K. and 15 deaths per year in Australia, with it being estimated that drugs may be the cause of as many as half of the anaphylactic deaths.

The aim of the device is to improve on existing in-vitro allergy detection technology that currently delivers a waiting time of over three hours and a cost of €30 ($32.91).

The new device would be the size of a small notebook computer and could be used in hospitals within the next five years, producing a result in less than 30 minutes at a cost of €2.40 ($2.63) per allergen. 

Related Articles Read More >

R&D winner of the day: Monolithic Fiber Array Launcher
R&D collaborations looking to build expertise, in this week’s R&D power index
Invention addresses the problems of running a red light at traffic intersections
Liberty Defense airport shoe screening technology earns prestigious national award
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2021 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars